Skip Navigation
Search Menu
Find an Expert

 


William Hikaru Matsui, M.D.

Photo of Dr. William Hikaru Matsui, M.D.

Professor of Oncology

Male

Expertise: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML), Hodgkin's Disease, Leukemia, Lymphoma, Medical Oncology, Multiple Myeloma, Non-Hodgkin's Lymphoma (NHL), Pancreatic Cancer ...read more

Research Interests: Hematologic Malignancies, Stem Cells

Request an Appointment

I live in Maryland

410-955-8964
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-2808
Fax: 410-614-7279

Background

William Matsui, M.D., is a Professor of Oncology at the Johns Hopkins University School of Medicine within the Division of Hematologic Malignancies. He directs the Multiple Myeloma Program at the Johns Hopkins Kimmel Cancer Center. Dr. Matsui received his medical degree from the University of California at San Francisco, and completed his residency at the University of Washington in Seattle. Dr. Matsui completed his fellowship training in medical oncology at the Johns Hopkins Kimmel Cancer Center, where he joined the faculty in 2002.

The primary focus of Dr. Matsui’s research is to better understand the role of cancer stem cells in hematologic malignancies and develop novel therapeutic strategies to target these cells.  Although stem cells are relatively rare in blood cancers, their capacity for self-renewal is likely responsible for the progression of disease through the continual production of new cancer cells. Dr. Matsui’s laboratory initially identified cancer stem cells in multiple myeloma and subsequently demonstrated that they are resistant to most current forms of therapy. These findings have suggested that myeloma stem cells can persist following treatment and lead to disease regrowth and relapse. More recently, Dr. Matsui and his team have identified several novel therapeutic strategies to target cancer stem cells including the Hedgehog signaling pathway, focal adhesion kinase, and telomerase. Many of these basic findings have served as the foundation for preclinical studies and clinical trials.  

As a clinician, Dr. Matsui's leadership role in the Multiple Myeloma Program has expanded the clinical scope of care for patients, including clinical trials, and plans are underway to integrate genomic and clinical data to better design treatment strategies for individual patients. In addition to novel clinical trials designed to target multiple myeloma cancer stem cells, the Multiple Myeloma program has explored several efforts to utilize the immune system to control and eradicate the disease. As a part of these immune based strategies, Dr. Matsui has a clinical interest in bone marrow transplantation, and has been actively expanding its use in multiple myeloma by focusing on the development of strategies to reduce the rates of graft versus host disease (GVHD), a major complication of allogeneic bone marrow transplantation (alloBMT). These efforts may allow a higher proportion of myeloma patients to undergo alloBMT, which currently remains the only curative option for the disease. 

Additionally, Dr. Matsui also serves as a reviewer and advisor for the National Institutes of Health and several foundations, including the Multiple Myeloma Research Foundation, the International Myeloma Foundation, and the Leukemia and Lymphoma Society.  He has published over a hundred scientific articles in major journals within the fields of hematology and oncology, and has been recognized by the Leukemia and Lymphoma Society, the American Society of Clinical Oncology, and the American Society of Clinical Investigation for his scholarly achievements.

...read more

Titles

  • Professor of Oncology

Education

Degrees

  • MD, University of California San Francisco (1995)

Residencies

  • University of Washington School of Medicine / Internal Medicine (1998)

Fellowships

  • Johns Hopkins University School of Medicine / Oncology (2000)
  • Johns Hopkins University School of Medicine / Oncology (2001)

Research & Publications

Lab

Lab Website: Matsui Laboratory

Selected Publications

Research Summary

In an increasing number of human malignancies, tumorigenic potential may be restricted to phenotypically and functionally distinct populations of cancer stem cells. Dr. Matsuis laboratory has studied multiple myeloma and found that the neoplastic plasma cells which characterize the disease are terminally differentiated and lack substantial proliferative potential. Instead, these mature tumor cells appear to arise from a relatively small population of tumor cells resembling normal memory B cells with the ability to both differentiate and self-renew. His laboratory subsequently demonstrated that most agents currently used to treat multiple myeloma patients are able to effectively inhibit plasma cells but are inactive against myeloma stem cells. These findings potentially explain why many current therapies are capable of producing clinical responses seen as decreased numbers of plasma cells but rarely cure the disease since myeloma stem cells may be spared and mediate tumor regrowth and clinical relapse. Dr. Matsuis laboratory has expanded these findings to other human tumors and has recently identified tumorigenic cell populations in Hodgkin lymphoma and pancreatic adenocarcinoma.

Self-renewal is the cellular process that likely maintains the malignant clone, and the Matsui lab has examined whether specific cellular pathways that mediate this property can serve as novel therapeutic targets. To this end, his laboratory has found that the Hedgehog signaling pathway required for proper embryonic development may regulate cancer stem cells in multiple myeloma, pancreatic cancer and brain tumors. His laboratory has also developed strategies based eliminating self-renewal potential through the forced induction of terminal differentiation. The Matsui group has successfully transformed these laboratory results into several novel clinical trials for patients with multiple myeloma, Hodgkin lymphoma, and myeloid leukemias. Finally, as a critical part of these clinical trials, we have begun to develop novel biomarkers strategies to quantify cancer stem cells in patients undergoing treatment.

Journal Citations

Fan, X.; Matsui, W.; Khaki, L.; Stearns, D.; Chun, J.; Li, Y.M.; Eberhart, C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006 Aug 1;66(15):7445-7452.

Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.

Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-434.

Huff, C.A.; Matsui, W.H.; Douglas Smith, B.; Jones, R.J. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006 Jun;42(9):1293-1297.

Matsui, W.H.; Brodsky, R.A.; Smith, B.D.; Borowitz, M.J.; Jones, R.J. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006 Mar;20(3):458-462.

Bar, E.E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A.L.; DiMeco, F.; Olivi, A.; Eberhart, C.G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007 Oct;25(10):2524-2533.

Bolanos-Meade, J.; Garrett-Mayer, E.; Luznik, L.; Anders, V.; Webb, J.; Fuchs, E.J.; Huff, C.A.; Matsui, W.; Borrello, I.M.; Brodsky, R.; Kasamon, Y.L.; Swinnen, L.J.; Flinn, I.W.; Ambinder, R.F.; Jones, R.J.; Hess, A.D.; Vogelsang, G.B. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-1191.

Chumsri, S.; Matsui, W.; Burger, A.M. Therapeutic implications of leukemic stem cell pathways. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6549-6554.

Lin, T.L.; Vala, M.S.; Barber, J.P.; Karp, J.E.; Smith, B.D.; Matsui, W.; Jones, R.J. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007 Sep;21(9):1915-1920.

Peacock, C.D.; Wang, Q.; Gesell, G.S.; Corcoran-Schwartz, I.M.; Jones, E.; Kim, J.; Devereux, W.L.; Rhodes, J.T.; Huff, C.A.; Beachy, P.A.; Watkins, D.N.; Matsui, W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-4053.

Huff, C.A.; Matsui, W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008 Jun 10;26(17):2895-2900.

Lauring, J.; Abukhdeir, A.M.; Konishi, H.; Garay, J.P.; Gustin, J.P.; Wang, Q.; Arceci, R.J.; Matsui, W.; Park, B.H. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood. 2008 Jan 15;111(2):856-864.

Luznik, L.; O'Donnell, P.V.; Symons, H.J.; Chen, A.R.; Leffell, M.S.; Zahurak, M.; Gooley, T.A.; Piantadosi, S.; Kaup, M.; Ambinder, R.F.; Huff, C.A.; Matsui, W.; Bolanos-Meade, J.; Borrello, I.; Powell, J.D.; Harrington, E.; Warnock, S.; Flowers, M.; Brodsky, R.A.; Sandmaier, B.M.; Storb, R.F.; Jones, R.J.; Fuchs, E.J. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-650.

Matsui, W.; Wang, Q.; Barber, J.P.; Brennan, S.; Smith, B.D.; Borrello, I.; McNiece, I.; Lin, L.; Ambinder, R.F.; Peacock, C.; Watkins, D.N.; Huff, C.A.; Jones, R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008 Jan 1;68(1):190-197.

Warlick, E.D.; O'Donnell, P.V.; Borowitz, M.; Grupka, N.; Decloe, L.; Garrett-Mayer, E.; Borrello, I.; Brodsky, R.; Fuchs, E.; Huff, C.A.; Luznik, L.; Matsui, W.; Ambinder, R.; Jones, R.J.; Douglas Smith, B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep;32(9):1439-1447.

Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.

Brandt, W.D.; Matsui, W.; Rosenberg, J.E.; He, X.; Ling, S.; Schaeffer, E.M.; Berman, D.M. Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev. 2009 Dec;28(3-4):291-304.

Ghosh, N.; Matsui, W. Cancer stem cells in multiple myeloma. Cancer Lett. 2009 May 8;277(1):1-7.
He, X.; Marchionni, L.; Hansel, D.E.; Yu, W.; Sood, A.; Yang, J.; Parmigiani, G.; Matsui, W.; Berman, D.M. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells. 2009 Jul;27(7):1487-1495.

Jiang, T.; Collins, B.J.; Jin, N.; Watkins, D.N.; Brock, M.V.; Matsui, W.; Nelkin, B.D.; Ball, D.W. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res. 2009 Feb 1;69(3):845-854.

Jones, R.J.; Gocke, C.D.; Kasamon, Y.L.; Miller, C.B.; Perkins, B.; Barber, J.P.; Vala, M.S.; Gerber, J.M.; Gellert, L.L.; Siedner, M.; Lemas, M.V.; Brennan, S.; Ambinder, R.F.; Matsui, W. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 2009 Jun 4;113(23):5920-5926.

Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biol Blood Marrow Transplant. 2009 Nov 16.Merchant, A.A.; Matsui, W. Smoothening the controversial role of hedgehog in hematopoiesis. Cell Stem Cell. 2009 Jun 5;4(6):470-471.

Mullendore, M.E.; Koorstra, J.B.; Li, Y.M.; Offerhaus, G.J.; Fan, X.; Henderson, C.M.; Matsui, W.; Eberhart, C.G.; Maitra, A.; Feldmann, G. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res. 2009 Apr 1;15(7):2291-2301.

Savage, W.J.; Barber, J.P.; Mukhina, G.L.; Hu, R.; Chen, G.; Matsui, W.; Thoburn, C.; Hess, A.D.; Cheng, L.; Jones, R.J.; Brodsky, R.A. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol. 2009 Jan;37(1):42-51.

Sun, P.; Xia, S.; Lal, B.; Eberhart, C.G.; Quinones-Hinojosa, A.; Maciaczyk, J.; Matsui, W.; Dimeco, F.; Piccirillo, S.M.; Vescovi, A.L.; Laterra, J. DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells. 2009 Jul;27(7):1473-1486.

Tjiang, T.; B.J., C.; Jin, N.; Brock, M.V.; Watkins, D.N.; Matsui, W.; Nelkin, B.D.; Ball, D.W. ASCL1 regulates CD133 and tumor-initiating capacity of SCLC. Cancer Research. 2009 (In Press).

Agarwal, J.R.; Matsui, W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem. 2010 Feb;10(2):116-120.

Bar, E.E.; Lin, A.; Mahairaki, V.; Matsui, W.; Eberhart, C.G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol. 2010 Sep;177(3):1491-1502.

Brennan, S.K.; Meade, B.; Wang, Q.; Merchant, A.A.; Kowalski, J.; Matsui, W. Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood. 2010 Nov 18;116(20):4185-4191.

Brennan, S.K.; Wang, Q.; Tressler, R.; Harley, C.; Go, N.; Bassett, E.; Huff, C.A.; Jones, R.J.; Matsui, W. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One. 2010;5(9).

Brodsky, R.A.; Chen, A.R.; Dorr, D.; Fuchs, E.J.; Huff, C.A.; Luznik, L.; Smith, B.D.; Matsui, W.H.; Goodman, S.N.; Ambinder, R.F.; Jones, R.J. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-2141.

Ishizawa, K.; Rasheed, Z.A.; Karisch, R.; Wang, Q.; Kowalski, J.; Susky, E.; Pereira, K.; Karamboulas, C.; Moghal, N.; Rajeshkumar, N.V.; Hidalgo, M.; Tsao, M.; Ailles, L.; Waddell, T.K.; Maitra, A.; Neel, B.G.; Matsui, W. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell. 2010 Sep 3;7(3):279-282.

Kasamon, Y.L.; Jones, R.J.; Brodsky, R.A.; Fuchs, E.J.; Matsui, W.; Luznik, L.; Powell, J.D.; Blackford, A.L.; Goodrich, A.; Gocke, C.D.; Abrams, R.A.; Ambinder, R.F.; Flinn, I.W. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol. 2010 Jun;21(6):1203-1210.

Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr;16(4):482-489.

Lim, Y.; Matsui, W. Hedgehog signaling in hematopoiesis. Crit Rev Eukaryot Gene Expr. 2010;20(2):129-139.

Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.

Merchant, A.; Joseph, G.; Wang, Q.; Brennan, S.; Matsui, W. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood. 2010 Mar 25;115(12):2391-2396.

Merchant, A.A.; Matsui, W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res. 2010 Jun 15;16(12):3130-3140.

Ohm, J.E.; Mali, P.; Van Neste, L.; Berman, D.M.; Liang, L.; Pandiyan, K.; Briggs, K.J.; Zhang, W.; Argani, P.; Simons, B.; Yu, W.; Matsui, W.; Van Criekinge, W.; Rassool, F.V.; Zambidis, E.; Schuebel, K.E.; Cope, L.; Yen, J.; Mohammad, H.P.; Cheng, L.; Baylin, S.B. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res. 2010 Oct 1;70(19):7662-7673.

Rajeshkumar, N.V.; Rasheed, Z.A.; Garcia-Garcia, E.; Lopez-Rios, F.; Fujiwara, K.; Matsui, W.H.; Hidalgo, M. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther. 2010 Sep;9(9):2582-2592.

Rasheed, Z.; Wang, Q.; Matsui, W. Isolation of stem cells from human pancreatic cancer xenografts. J Vis Exp. 2010 (43).

Rasheed, Z.A.; Yang, J.; Wang, Q.; Kowalski, J.; Freed, I.; Murter, C.; Hong, S.M.; Koorstra, J.B.; Rajeshkumar, N.V.; He, X.; Goggins, M.; Iacobuzio-Donahue, C.; Berman, D.M.; Laheru, D.; Jimeno, A.; Hidalgo, M.; Maitra, A.; Matsui, W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010 Mar 3;102(5):340-351.

Shim, J.S.; Matsui, Y.; Bhat, S.; Nacev, B.A.; Xu, J.; Bhang, H.E.; Dhara, S.; Han, K.C.; Chong, C.R.; Pomper, M.G.; So, A.; Liu, J.O. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst. 2010 Dec 15;102(24):1855-1873.

Smith, B.D.; Jones, R.J.; Cho, E.; Kowalski, J.; Karp, J.E.; Gore, S.D.; Vala, M.; Meade, B.; Baker, S.D.; Zhao, M.; Piantadosi, S.; Zhang, Z.; Blumenthal, G.; Warlick, E.D.; Brodsky, R.A.; Murgo, A.; Rudek, M.A.; Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011 Jan;35(1):87-94.

Huff, CA, Matsui, WH, Smith, BD, Jones, RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006; 107:431-434.

Matsui, W, Brodsky, RA, Smith, BD, Borowitz,MJ, Jones, RJ. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006; 20:458-462.

Huff, CA, Matsui, W, Smith, BD, Jones, RJ. Strategies to eliminate cancer stem cells: clinical implications. European Journal of Cancer. 2006; 42:1293-1297.

Fan, X, Matsui, W, Khaki, L., Stearns, D., Chun, J., Li, YM., Eberhart, CG. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006; 66:7445-7452.

Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer, E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biology of Blood and Marrow Transplantation. 2006; 12:414-421.

Jones, R.J., Matsui, W. Cancer stem cells: from bench to bedside. Biology of Blood and Marrow Transplantation. 2007; 13 Suppl 1:47-52.

Peacock, CD, Wang, Q, Gessell, GS, Corcoran-Scwartz, IM, Jones, E, Kim, J, Devereux, WL, Rhodes, JT, Huff, CA, Beachy, PA, Watkins, DN, Matsui, W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences. 2007; 104:4048-4053.

Feldmann, G, Dhara, S, Fendrich, V, Bedja, D, Beaty, R, Mullendore, M, Karikari, C, Alvarez, H, Iacobuzio-Donahue, C, Jimeno, A, Gabrielson, KL, Matsui, W, Maitra, A. Blockade of Hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Research. 2007; 67: 2187-96.

Lin TL, Vala MS, Barber JP, Karp JE, Smith BD, Matsui W, Jones, RJ. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007; 21:1915-1920.

Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Vescovi AL, Piccirillo S, Dimeco F, Olivi A, Eberhart CG. Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007; 25:2524-2533.

Bolaos-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biology of Blood and Marrow Transplantation. 2007. 13:1185-1191.

Chumsri S, Matsui W, Burger AM. Therapeutic Implications of Leukemic Stem Cell Pathways. Clinical Cancer Research. 2007; 13:6549-6554.

Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH. The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood. 2008; 111:856-864.

Matsui W, Wang Q, Barber J, Brennan S, Smith B, Borrello I, McNiece I, Lin L, Ambinder R, Peacock C, Watkins N, Huff C, Jones R. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Research. 2008; 68:190-197.

Warlick ED, ODonnell PV, Borowitz M, Grupka N, Decloe L, Garrett-Mayer E, Borrello I, Brodsky R, Fuchs E, Huff CA, Luznik L, Matsui W, Ambinder R, Jones RJ, Smith BD. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leukemia Research. 2008; 32:1439-1447.

Luznik L, O'Donnell P, Symons H, Chen A, Leffell M, Zahurak M, Gooley T, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation. 2008; 14:641-650.

Huff CA and Matsui W. Multiple myeloma cancer stem cells. Journal of Clinical Oncology. 2008; 28:2895-2900.

Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra J, Habbe N, Karikari C, Mullendore M, Gabrielson KL, Sharma R, Matsui W, Maitra A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Molecular Cancer Therapeutics. 2008; 7:2725-2735.

Ghosh N. and Matsui W. Cancer stem cells in multiple myeloma. Cancer Letters. 2008; 277:1-7.

Bolaos-Meade J, Luznik L, Muth M, Matsui W, Huff CA, Smith BD, Levy MY, Kasamon YL, Swinnen L, Powell J, Brodsky R, Ambinder RF, Jones RJ, Fuchs EJ. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplantation. 2009; 43:477-480.

Activities & Honors

Honors

  • Kimmel Foundation Scholar, Sidney Kimmel Foundation for Cancer Research, 2007 - 2009
  • Leukemia and Lymphoma Society Scholar in Clinical Research, The Leukemia and Lymphoma Society, 2009 - 2014

Memberships

  • American Association of Cancer Research
  • American Society for Blood and Marrow Transplantation
  • American Society of Clinical Oncology
  • American Society of Hematology
  • International Society for Stem Cell Research
Is this you? Edit Profile